Trial
NCT02277392
A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
—
Condition
Ovarian, Fallopian Tube and Peritoneal Cancer
Intervention
Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-09-27